<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053205</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 043 CT</org_study_id>
    <nct_id>NCT04053205</nct_id>
  </id_info>
  <brief_title>A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital, Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Tumor Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of&#xD;
      Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric&#xD;
      or Gastroesophageal Junction Cancer patients, to ensure adequate treatment dosage for further&#xD;
      study. Meanwhile, the study also evaluate Pharmacokinetics of Gentuximab Injection at&#xD;
      different dosage in combination with Paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes dose-limiting toxicity （DLT）observing period and randomization period with&#xD;
      two cohorts as low-dose group（Gentuximab Injection 8mg/kg+ paclitaxel） and high-dose&#xD;
      group（Gentuximab Injection 12mg/kg+ paclitaxel）. During the study，the anti-cancer efficacy,&#xD;
      safety and anti-drug antibody were evaluated in all patients. DLT observation is only to&#xD;
      subjects enrolled in DLT observation period and it lasts one treatment period. PK were doing&#xD;
      in part of subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLT)</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>Number of Participants With One or More Drug-Related Adverse Events (AEs) defined as DLT in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs or SAEs</measure>
    <time_frame>Baseline through Study Completion, about 24 weeks</time_frame>
    <description>Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate（ORR）</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>Proportion of Participants With CR and PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>The time from randomization to the patient tumor progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>Proportion of Participants With CR, PR and SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progress (TTP)</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>The time from randomization to the patient tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-failure (TTF)</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>The time from randomization to the patient withdraw from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody</measure>
    <time_frame>Up to 6 cycles (28 days for every cycle)</time_frame>
    <description>Number of Participants With Anti-drug Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Cmax</measure>
    <time_frame>Cycle 1(day1-day 15)&amp; Cycle 2(day 15-day26) &amp; Cycle 3(day 1) (28 days for every cycle)</time_frame>
    <description>Maximum Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC)</measure>
    <time_frame>Cycle 1(day1-day 15)&amp; Cycle 2(day 15-day26) &amp; Cycle 3(day 1) Cycle 1(day1-day 15)&amp; Cycle 2(day 15-day26) &amp; Cycle 3(day 1) （28 days for every cycle）</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Advanced Gastric or Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>1 Gentuximab+ Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Gentuximab+ Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentuximab</intervention_name>
    <description>Administered intravenously (IV)</description>
    <arm_group_label>1 Gentuximab+ Paclitaxel</arm_group_label>
    <arm_group_label>2 Gentuximab+ Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously (IV)</description>
    <arm_group_label>1 Gentuximab+ Paclitaxel</arm_group_label>
    <arm_group_label>2 Gentuximab+ Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject can understand the process and methods of the study, complete the study in&#xD;
             accordance with the protocol and is willing to sign a written informed consent.&#xD;
&#xD;
          -  Male or female. aged between 18 and 75 years&#xD;
&#xD;
          -  Histopathologically confirmed advanced advanced gastric or gastroesophageal junction&#xD;
             cancer, and Documented progression during first-line fluoropyrimidine- and platinum-&#xD;
             containing chemotherapy, or during the 3 months following the last cycle of such&#xD;
             chemotherapy (or during the 6 months following the last dose of adjuvant therapy or&#xD;
             new adjuvant therapy containing fluoropyrimidine and platinium).&#xD;
&#xD;
          -  At least one Measurable lesion.&#xD;
&#xD;
          -  ECOG Performance status (PS) score, 0-1 level.&#xD;
&#xD;
          -  A life expectancy of &gt;3 months.&#xD;
&#xD;
          -  Adequate hematologic function, as defined by: Absolute neutrophil count (ANC)&#xD;
             ≥1.5×109/L; hemoglobin concentration ≥90g/L (allowing blood transfusion); and platelet&#xD;
             count ≥80×109/L.&#xD;
&#xD;
          -  Adequate hepatic function, as defined by: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5&#xD;
             × ULN (liver metastases patients ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN).&#xD;
&#xD;
          -  Adequate renal function, as defined by: serum creatinine level≤ 1.5 × ULN, or&#xD;
             creatinine clearance ≥ 50ml / min when serum creatinine level&gt; 1.5 × ULN.&#xD;
&#xD;
          -  Adequate coagulation function, as defined by: International normalized ratio (INR)&#xD;
             ≤1.5× ULN, activated partial thromboplastin time (aPTT) ≤1.5 x ULN.&#xD;
&#xD;
          -  24-hour urine protein quantitation is &lt;1g（24-hour urine protein quantitative test&#xD;
             should be performed when urine protein ≥1+ is found during screening visit）.&#xD;
&#xD;
          -  Subjects (male and female) who have fertility must agree to use reliable contraceptive&#xD;
             methods during the trial and in 3 months after the last administration. Female&#xD;
             subjects in childbearing age must be negative for blood pregnancy test prior to&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously administrated with anti-angiogenic drugs or paclitaxel.&#xD;
&#xD;
          -  Systematic anti-tumor therapy (non-anti-angiogenic drugs or paclitaxel) such as&#xD;
             chemotherapy, radiotherapy, macromolecular targeted therapy, immunotherapy, endocrine&#xD;
             therapy, etc. within 4 weeks before the first dose of investigational drug, except for&#xD;
             the following: nitrourea or mitomycin C is within 6 weeks before the first dose, oral&#xD;
             fluorouracil and small molecule targeted drugs are within 2 weeks or 5 half-life of&#xD;
             the drug(whichever is longer) before the first dose，Chinese medicine with anti-cancer&#xD;
             indications is within 2 weeks before the first dose.&#xD;
&#xD;
          -  Has participated in a clinical study of a non-approved experimental agent within 4&#xD;
             weeks prior to screening visit.&#xD;
&#xD;
          -  Has undergone major surgery within 4 weeks before screening visit (not including&#xD;
             needle biopsy)， or would undergo planned surgery during the study.&#xD;
&#xD;
          -  Subject with positive HCV-Ab, Anti-HIV or TP-Ab, or positive HBS-Ag with copies of HBV&#xD;
             DNA &gt; ULN.&#xD;
&#xD;
          -  Patients with previously confirmed malignant tumors.&#xD;
&#xD;
          -  History of arterial thrombosis or deep vein thrombosis within 6 months prior to&#xD;
             screening, or a bleeding event no less than Grade level 3 within 2 months prior to&#xD;
             screening， or the investigator determines that there is a risk of bleeding.&#xD;
&#xD;
          -  History of severe cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
          -  Subjects with confirmed brain tumor metastases，but subjects in steady situation can be&#xD;
             enrolled.&#xD;
&#xD;
          -  Active bleeding confirmed by gastroscopy when fecal occult blood positive (only&#xD;
             subjects with primary lesions not removed need to do fecal occult blood test.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 12 months before screening visit.&#xD;
&#xD;
          -  Thoracic，abdominal or pericardial effusion that cannot be controlled by repeated&#xD;
             drainage or with obvious symptoms.&#xD;
&#xD;
          -  Has a nonhealing wound, serious ulcer, or unrecovered bone fracture.&#xD;
&#xD;
          -  Active infections requiring systemic treatment, including but not limited to active&#xD;
             tuberculosis.&#xD;
&#xD;
          -  Using anticoagulation and antiplatelet drugs.&#xD;
&#xD;
          -  Female subjects who is pregnant (confirmed by urine or serum pregnancy test) or&#xD;
             lactating.&#xD;
&#xD;
          -  Has a known serious allergy reaction to recombination monoclonal antibody (MAb) drug,&#xD;
             ,or infusion reaction.&#xD;
&#xD;
          -  Has known alcohol or drug dependency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Siqin Wang</last_name>
    <email>wangsiqin@gensci-china.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Li</last_name>
    <phone>13761222111</phone>
    <email>tianyoulijin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianwei Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhong Deng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuxian Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingxia Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhong Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongming Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Nong Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianglin Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weiyi Huang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

